Profile
Hana Chen-Walden worked as the Director-International Regulatory Affairs at Covalent Group, Inc. from 2000 to 2003.
She then served as the Chief Medical Director at Boston Therapeutics, Inc. and as an Independent Director at BioXyTran, Inc. Dr. Chen-Walden holds a doctorate degree from Tel-Aviv University.
Former positions of Hana Chen-Walden
| Companies | Position | End |
|---|---|---|
| BIOXYTRAN, INC. | Director/Board Member | 2024-04-18 |
| Covalent Group, Inc. | General Counsel | 2002-12-31 |
| NANOMIX CORPORATION | Chief Tech/Sci/R&D Officer | - |
Training of Hana Chen-Walden
| Tel-Aviv University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BIOXYTRAN, INC. | Health Technology |
| Private companies | 2 |
|---|---|
| Covalent Group, Inc. | Commercial Services |
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
- Stock Market
- Insiders
- Hana Chen-Walden
